mTORC1-mediated translational elongation limits intestinal tumour initiation and growth

Faller, W. et al. (2015) mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature, 517(7535), pp. 497-500. (doi:10.1038/nature13896) (PMID:25383520) (PMCID:PMC4304784)

Faller, W. et al. (2015) mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature, 517(7535), pp. 497-500. (doi:10.1038/nature13896) (PMID:25383520) (PMCID:PMC4304784)

Full text not currently available from Enlighten.

Abstract

Inactivation of APC is a strongly predisposing event in the development of colorectal cancer1, 2, prompting the search for vulnerabilities specific to cells that have lost APC function. Signalling through the mTOR pathway is known to be required for epithelial cell proliferation and tumour growth3, 4, 5, and the current paradigm suggests that a critical function of mTOR activity is to upregulate translational initiation through phosphorylation of 4EBP1 (refs 6, 7). This model predicts that the mTOR inhibitor rapamycin, which does not efficiently inhibit 4EBP1 (ref. 8), would be ineffective in limiting cancer progression in APC-deficient lesions. Here we show in mice that mTOR complex 1 (mTORC1) activity is absolutely required for the proliferation of Apc-deficient (but not wild-type) enterocytes, revealing an unexpected opportunity for therapeutic intervention. Although APC-deficient cells show the expected increases in protein synthesis, our study reveals that it is translation elongation, and not initiation, which is the rate-limiting component. Mechanistically, mTORC1-mediated inhibition of eEF2 kinase is required for the proliferation of APC-deficient cells. Importantly, treatment of established APC-deficient adenomas with rapamycin (which can target eEF2 through the mTORC1–S6K–eEF2K axis) causes tumour cells to undergo growth arrest and differentiation. Taken together, our data suggest that inhibition of translation elongation using existing, clinically approved drugs, such as the rapalogs, would provide clear therapeutic benefit for patients at high risk of developing colorectal cancer.

Item Type:Articles (Letter)
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Vidal, Dr Marcos and Casey, Dr Helen and Faller, Dr William and Huels, Mr David and Cordero, Dr Julia and Myant, Dr Kevin and Radulescu, Dr Sorina and Ridgway, Dr Rachel and Karim, Ms Saadia and Sansom, Professor Owen and Bushell, Professor Martin and Scopelliti, Mr Alessandro and Jamieson, Mr Thomas
Authors: Faller, W., Jackson, T. J., Knight, J. R.P., Ridgway, R. A., Jamieson, T., Karim, S. A., Jones, C., Radulescu, S., Huels, D. J., Myant, K. B., Dudek, K. M., Casey, H. A., Scopelliti, A., Cordero, J., Vidal, M., Pende, M., Ryazanov, A. G., Sonenberg, N., Meyuhas, O., Hall, M. N., Bushell, M., Willis, A. E., and Sansom, O. J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Nature
Publisher:Nature Publishing Group
ISSN:0028-0836
ISSN (Online):1476-4687
Published Online:05 November 2014

University Staff: Request a correction | Enlighten Editors: Update this record